No association between vulvovaginitis-bacterial vaginosis, related drug treatments of pregnant women, and congenital abnormalities in their offspring - A population-based case-control study

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The possible association between prospectively and medically recorded vulvovaginitis-bacterial vaginosis (VV-BV) and different congenital abnormalities (CA) has not been studied. The data set of the population-based Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 were evaluated, i.e. 22,843 pregnant women who had newborns or fetuses with congenital abnormality (cases) and 38,151 pregnant women who delivered newborn babies without any congenital abnormality (controls). The main outcome measures were different congenital abnormalities. Of 22,843 cases with CA, 1,536 (6.7%) had mothers with VV-BV, while of 38,151 matched controls without CA, 2,698 (7.1%) had mothers with VV-BV in the second and/or third gestational month of pregnancy. Nearly all pregnant women with VV-BV were treated during pregnancy, but a higher risk for the total group of CAs (adjusted POR with 95% CI: 0.95, 0.89-1.02) or any CA group was not found. In addition, the risk for total CAs was significantly lower in cases born to mothers with VV-BV and appropriate treatment than born to mothers with VV-BV but without treatment. Thus maternal VV-BV needs treatment during pregnancy as well, because it helps reduce the rate of preterm birth without a risk for CAs.

Original languageEnglish
Pages (from-to)332-340
Number of pages9
JournalCentral European Journal of Medicine
Volume3
Issue number3
DOIs
Publication statusPublished - Sep 2008

Fingerprint

Vulvovaginitis
Bacterial Vaginosis
Case-Control Studies
Pregnant Women
Pharmaceutical Preparations
Population
Mothers
Therapeutics
Newborn Infant
High-Risk Pregnancy
Pregnancy
Premature Birth
Fetus
Outcome Assessment (Health Care)

Keywords

  • Congenital abnormalities
  • Population-based case-control study
  • Vulvovaginitis-bacterial vaginosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{079226dc4a5049089d6c5e4eefc04f24,
title = "No association between vulvovaginitis-bacterial vaginosis, related drug treatments of pregnant women, and congenital abnormalities in their offspring - A population-based case-control study",
abstract = "The possible association between prospectively and medically recorded vulvovaginitis-bacterial vaginosis (VV-BV) and different congenital abnormalities (CA) has not been studied. The data set of the population-based Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 were evaluated, i.e. 22,843 pregnant women who had newborns or fetuses with congenital abnormality (cases) and 38,151 pregnant women who delivered newborn babies without any congenital abnormality (controls). The main outcome measures were different congenital abnormalities. Of 22,843 cases with CA, 1,536 (6.7{\%}) had mothers with VV-BV, while of 38,151 matched controls without CA, 2,698 (7.1{\%}) had mothers with VV-BV in the second and/or third gestational month of pregnancy. Nearly all pregnant women with VV-BV were treated during pregnancy, but a higher risk for the total group of CAs (adjusted POR with 95{\%} CI: 0.95, 0.89-1.02) or any CA group was not found. In addition, the risk for total CAs was significantly lower in cases born to mothers with VV-BV and appropriate treatment than born to mothers with VV-BV but without treatment. Thus maternal VV-BV needs treatment during pregnancy as well, because it helps reduce the rate of preterm birth without a risk for CAs.",
keywords = "Congenital abnormalities, Population-based case-control study, Vulvovaginitis-bacterial vaginosis",
author = "N. {\'A}cs and F. B{\'a}nhidy and E. Puh{\'o} and E. Czeizel",
year = "2008",
month = "9",
doi = "10.2478/s11536-008-0027-9",
language = "English",
volume = "3",
pages = "332--340",
journal = "Central European Journal of Medicine",
issn = "1895-1058",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - No association between vulvovaginitis-bacterial vaginosis, related drug treatments of pregnant women, and congenital abnormalities in their offspring - A population-based case-control study

AU - Ács, N.

AU - Bánhidy, F.

AU - Puhó, E.

AU - Czeizel, E.

PY - 2008/9

Y1 - 2008/9

N2 - The possible association between prospectively and medically recorded vulvovaginitis-bacterial vaginosis (VV-BV) and different congenital abnormalities (CA) has not been studied. The data set of the population-based Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 were evaluated, i.e. 22,843 pregnant women who had newborns or fetuses with congenital abnormality (cases) and 38,151 pregnant women who delivered newborn babies without any congenital abnormality (controls). The main outcome measures were different congenital abnormalities. Of 22,843 cases with CA, 1,536 (6.7%) had mothers with VV-BV, while of 38,151 matched controls without CA, 2,698 (7.1%) had mothers with VV-BV in the second and/or third gestational month of pregnancy. Nearly all pregnant women with VV-BV were treated during pregnancy, but a higher risk for the total group of CAs (adjusted POR with 95% CI: 0.95, 0.89-1.02) or any CA group was not found. In addition, the risk for total CAs was significantly lower in cases born to mothers with VV-BV and appropriate treatment than born to mothers with VV-BV but without treatment. Thus maternal VV-BV needs treatment during pregnancy as well, because it helps reduce the rate of preterm birth without a risk for CAs.

AB - The possible association between prospectively and medically recorded vulvovaginitis-bacterial vaginosis (VV-BV) and different congenital abnormalities (CA) has not been studied. The data set of the population-based Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 were evaluated, i.e. 22,843 pregnant women who had newborns or fetuses with congenital abnormality (cases) and 38,151 pregnant women who delivered newborn babies without any congenital abnormality (controls). The main outcome measures were different congenital abnormalities. Of 22,843 cases with CA, 1,536 (6.7%) had mothers with VV-BV, while of 38,151 matched controls without CA, 2,698 (7.1%) had mothers with VV-BV in the second and/or third gestational month of pregnancy. Nearly all pregnant women with VV-BV were treated during pregnancy, but a higher risk for the total group of CAs (adjusted POR with 95% CI: 0.95, 0.89-1.02) or any CA group was not found. In addition, the risk for total CAs was significantly lower in cases born to mothers with VV-BV and appropriate treatment than born to mothers with VV-BV but without treatment. Thus maternal VV-BV needs treatment during pregnancy as well, because it helps reduce the rate of preterm birth without a risk for CAs.

KW - Congenital abnormalities

KW - Population-based case-control study

KW - Vulvovaginitis-bacterial vaginosis

UR - http://www.scopus.com/inward/record.url?scp=47249100241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249100241&partnerID=8YFLogxK

U2 - 10.2478/s11536-008-0027-9

DO - 10.2478/s11536-008-0027-9

M3 - Article

AN - SCOPUS:47249100241

VL - 3

SP - 332

EP - 340

JO - Central European Journal of Medicine

JF - Central European Journal of Medicine

SN - 1895-1058

IS - 3

ER -